
Krishan R Jethwa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6027811/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma. Cancer Research, 2013, 73, 3913-3926.	0.9	223
2	Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology, 2018, 8, 28-39.	2.1	140
3	A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases. Neuro-Oncology, 2019, 21, 1049-1059.	1.2	80
4	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology, 2018, 20, 1652-1660.	1.2	47
5	Post-mastectomy intensity modulated proton therapy after immediate breast reconstruction: Initial report of reconstruction outcomes and predictors of complications. Radiotherapy and Oncology, 2019, 140, 76-83.	0.6	34
6	Delineation of Internal Mammary Nodal Target Volumes in Breast Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 762-769.	0.8	32
7	Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. International Journal of Radiation Oncology Biology Physics, 2019, 104, 75-82.	0.8	27
8	Immediate tissue expander or implant-based breast reconstruction does not compromise the oncologic delivery of post-mastectomy radiotherapy (PMRT). Breast Cancer Research and Treatment, 2017, 164, 237-244.	2.5	26
9	3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen. Radiation Oncology, 2019, 14, 211.	2.7	23
10	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.8	22
11	Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Advances in Radiation Oncology, 2018, 3, 314-321.	1.2	20
12	Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. Radiotherapy and Oncology, 2020, 146, 29-36.	0.6	20
13	Incorporation of Biologic Response Variance Modeling Into the Clinic: Limiting Risk of Brachial Plexopathy and Other Late Effects of Breast Cancer Proton Beam Therapy. Practical Radiation Oncology, 2020, 10, e71-e81.	2.1	15
14	Leptomeningeal disease and neurologic death after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis. Advances in Radiation Oncology, 2021, 6, 100644.	1.2	13
15	The emerging role of proton therapy for esophagus cancer. Journal of Gastrointestinal Oncology, 2020, 11, 144-156.	1.4	12
16	miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clinical Investigation, 2011, 1, 1637-1650.	0.0	8
17	The incidence of cerebrovascular accidents and second brain tumors in patients with pituitary adenoma: a population-based study. Neuro-Oncology Practice, 2014, 1, 22-28.	1.6	8
18	Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience. Breast Cancer Research and Treatment, 2018, 169, 189-196.	2.5	8

Krishan R Jethwa

#	Article	IF	CITATIONS
19	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clinical and Translational Radiation Oncology, 2021, 27, 15-23.	1.7	8
20	Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. Journal of Gastrointestinal Oncology, 2020, 11, 1408-1420.	1.4	8
21	Time to Reconsider Staging Laparoscopy in Pancreatic Cancer?. Journal of Clinical Oncology, 2020, 38, 2944-2945.	1.6	7
22	Comparison of Oncologic Outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and En Bloc Resection for Sacral Chordoma. JAMA Network Open, 2022, 5, e2141927.	5.9	7
23	Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. Clinical and Translational Radiation Oncology, 2021, 28, 17-23.	1.7	6
24	The Importance of Verification CT-QA Scans in Patients Treated with IMPT for Head and Neck Cancers. International Journal of Particle Therapy, 2020, 7, 41-53.	1.8	6
25	Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. Journal of Contemporary Brachytherapy, 2016, 5, 371-378.	0.9	5
26	Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study. Practical Radiation Oncology, 2021, 11, e63-e69.	2.1	5
27	Proton beam radiotherapy for esophagus cancer: state of the art. Journal of Thoracic Disease, 2020, 12, 7002-7010.	1.4	4
28	Clinical Implementation of Preoperative Short-Course Pencil Beam Scanning Proton Therapy for Patients With Rectal Cancer. Advances in Radiation Oncology, 2020, 5, 865-870.	1.2	4
29	Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research, 2021, 10, 2571-2585.	1.0	4
30	Lymph node–directed simultaneous integrated boost in patients with clinically lymph node–positive cervical cancer treated with definitive chemoradiotherapy: clinical outcomes and toxicity. Journal of Radiation Oncology, 2020, 9, 103-111.	0.7	3
31	Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. Oncologist, 2021, 26, 660-667.	3.7	3
32	Patterns of recurrence after primary local therapy for pancreatic ductal adenocarcinoma – a critical review of rationale and target delineation for (neo)adjuvant radiotherapy. Practical Radiation Oncology, 2022, , .	2.1	3
33	Timing, presentation, and patterns of failure of leptomeningeal disease after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis Journal of Clinical Oncology, 2018, 36, 2070-2070.	1.6	2
34	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder, 2018, 5, e34.	0.2	2
35	The use of intraoperative radiation therapy in the management of locally recurrent rectal cancer. Seminars in Colon and Rectal Surgery, 2020, 31, 100763.	0.3	1
36	Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis. Cancer Medicine, 2021, 10, 3575-3583.	2.8	1

#	Article	IF	CITATIONS
37	Abstract B62: miR-124 systemically enhances antitumor clearance by inhibiting STAT3 signaling and reversing glioma-associated immune suppression , 2013, , .		1
38	Does the dural resection bed need to be irradiated? Patterns of recurrence and implications for postoperative radiotherapy for temporal lobe gliomas. Neuro-Oncology Practice, 2021, 8, 190-198.	1.6	1
39	Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole-Brain Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100949.	1.2	1
40	A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	1
41	Prostate Volume Before and After Neoadjuvant Cytoreductive Androgen Suppression and Potential Predictors of Cytoreductive Efficacy. Brachytherapy, 2014, 13, S110-S111.	0.5	0
42	In Reply to Hannoun-Levi and Hannoun. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1177-1179.	0.8	0
43	RTHP-30. DOES THE TEMPORAL LOBECTOMY CAVITY NEED TO BE IRRADIATED? PATTERNS OF RECURRENCE AND IMPLICATIONS FOR POSTOPERATIVE RADIATION TREATMENT FIELD DESIGN FOR TEMPORAL LOBE GLIOMAS Neuro-Oncology, 2019, 21, vi216-vi216.	1.2	0
44	Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Advances in Radiation Oncology, 2020, 5, 951-958.	1.2	0
45	The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, E31-E32.	0.8	0
46	Mo1410 CURATIVE-INTENT CHEMORADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE, EXTRA-HEPATIC CHOLANGIOCARCINOMA. Gastroenterology, 2020, 158, S-1398-S-1399.	1.3	0
47	Abstract B15: Association between travel distance to a comprehensive cancer center and breast cancer stage, treatment, and outcomes in a rural state. , 2013, , .		0
48	Leptomeningeal disease after surgical resection and radiosurgery for brain metastases and neurologic death: A multi-institutional analysis Journal of Clinical Oncology, 2020, 38, 2524-2524.	1.6	0
49	Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era Journal of Clinical Oncology, 2020, 38, 748-748.	1.6	0
50	Research on Anal Squamous Cell Carcinoma. Cancers, 2022, 14, 42.	3.7	0